Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

“We had been working in the muscarinic receptor space for almost 20 years,” says Samir Siddhanti, Neurocrine’s executive director of business development. The Neurocrine team was aware of ...

At present no definitive medical treatment exists for acute pancreatitis. [9,10] Pirenzepine has shown encouraging positive responses and a low incidence of adverse effects when used to treat ...

A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

Researchers discovered that xanomeline-trospium, a new-generation antipsychotic devoid of D2 dopamine receptor blocking ...

The latest candidate to move into phase 2 is NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is the most advanced candidate in a $2.6 billion alliance with Neurocrine signed ...

Division of Psychological Medicine and Clinical Neurosciences, and Neuroscience and Mental Health Innovation Institute, Cardiff University, Cardiff, UK Antipsychotic medications targeting dopamine ...

Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and ...

while Cobenfy is a selective and direct agonist of two muscarinic receptors - M1 and M4. The other difference is that emraclidine's effects are limited to the central nervous system and that ...